News | November 14, 2024
AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Combined capabilities to drive novel healthcare applications presented at MEDICA 2024
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Subscribe To Our Newsletter & Stay Updated
